Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
about
Rosiglitazone for type 2 diabetes mellitusNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewRegulatory challenges for new drugs to treat obesity and comorbid metabolic disordersReview of the Structural and Dynamic Mechanisms of PPARγ Partial AgonismEffect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients.Management of type 2 diabetes mellitus. Role of thiazolidinediones.Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?Current therapeutic options in type 2 diabetes mellitus: a practical approachInvolvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.Where thiazolidinediones will fit.PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.Counseling patients with type 2 diabetes and insulin resistance in the outpatient setting.Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome.Pharmacologic treatment of type 2 diabetic dyslipidemia.Diabetes mellitus: new challenges and innovative therapies.Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response.Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectivesThe effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patientsThiazolidinedione derivatives in diabetes and cardiovascular disease: an update.Redefining the role of thiazolidinediones in the management of type 2 diabetesPeroxisome proliferator-activated receptor-gamma agonist improves skeletal muscle insulin signaling in the pregestational intrauterine growth-restricted rat offspring.Cardiovascular risk of rosiglitazone: another perspective.Systems pharmacology of adverse event mitigation by drug combinationsAn observational study of the effect of two thiazolidinediones on blood lipid levels: Rosiglitazone and pioglitazone in routine clinical practiceA review of the response to oral antidiabetes agents in patients with type 2 diabetes.Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.The importance of synthetic drugs for type 2 diabetes drug discovery.Exercise- and resveratrol-mediated alterations in adipose tissue metabolism.Pharmacologic treatment of type 2 diabetes: oral medications.Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.Dapagliflozin combination therapy in type 2 diabetes mellitus.
P2860
Q24243875-D881DCF7-70C2-4C50-8FF6-4F6E1220CFEDQ24561401-8B095CF2-6480-4EB0-A9B5-DC991C269655Q24658031-8ABFBCFD-3244-443A-B6C6-E99CDB86687CQ26782232-51AE544A-CB4C-452D-93BC-3EFD2DFC19CAQ30738419-D1E62331-7F95-4BD7-BC55-824ED7097116Q33210296-CC6B7EC3-5829-49AD-8124-274C8A645676Q33216408-66CDE3BB-226D-423A-9069-2265FFD3F309Q33654306-985DB12C-7643-483C-9E73-E1B2DB0D9BB3Q33723387-7EB0D0C1-FFCA-4558-86A3-6582C45EEFEBQ34025180-74968B12-7296-4814-A2F5-0733528C3617Q34395184-177CA4F8-E2E9-41F2-A99A-03C6F291B049Q34421542-7BFD7EBA-4323-4CCC-951A-2D81534585EAQ34580999-355AE5AD-181E-4860-8E86-0BEE25EB9E04Q34689526-650845C6-E178-4D4D-AC85-E790A940D8CAQ35044470-B7D77562-D6D8-49A2-8D1F-4515B432DCDFQ35049153-C19767B6-3030-40AB-819E-37C7C19DE99FQ35141084-44F7C890-42D0-428A-B67F-CF7449A96E5FQ35186537-2035301F-5365-4147-AA86-F94711039294Q35207615-BED0AB29-8DAA-4EB0-A606-A4B7F6BE9E49Q35976827-2441D5B1-0104-4413-8063-F962ECC689E1Q36117595-53BEB1E3-A51C-4F52-8B99-6CAC0D435738Q36320556-FD39D538-F97A-4B98-B4F4-45CD7EB14386Q36512559-3946E56A-EE9B-45E0-BBC7-2FE4B2A920CAQ36519207-44FE8CB7-1DBD-4989-8959-FC7237FBD367Q36644432-2EE8C082-3C72-435B-8823-B987B899C0C3Q36812788-B0C64745-9DCA-428A-8F2D-30BF5111916AQ36993971-EE1D68DA-0998-475A-9664-20151FADB4C9Q37142138-B1A97CCD-3937-4B99-BF2C-FD591FCAD3F4Q37167551-613EE578-7882-4042-8148-F376CA8878D0Q37298063-A0FD1E04-6110-4B98-8251-C6957FC1EB09Q37322689-FFAF6D56-2077-44AE-AF5A-697D6F0D4A5AQ37658567-C3CD5B85-3169-4B76-84A2-D4EAE460D7A8Q37719114-1C82FBF8-56C0-4AE9-9877-02C69B1FFC16Q37750257-9FC72689-55D8-4BB3-9A95-096EF0778456Q37835820-1BAF84A2-C05E-4900-9BAB-FBC191206A8CQ38139508-94ED74FF-42F7-478B-8F3B-2D779F9E98E6Q38183160-62BB34AD-E6C0-40E3-B7D8-B2305EA3CB3FQ38350347-208412ED-D59C-47C7-9BE5-23E1C53EC5A7Q38511039-FC691BE1-0B78-44AF-82C3-37FFFF4AE0EAQ38634051-3A5DAE61-3317-4881-A5EF-C9500769F012
P2860
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Once- and twice-daily dosing w ...... patients with type 2 diabetes.
@ast
Once- and twice-daily dosing w ...... patients with type 2 diabetes.
@en
type
label
Once- and twice-daily dosing w ...... patients with type 2 diabetes.
@ast
Once- and twice-daily dosing w ...... patients with type 2 diabetes.
@en
prefLabel
Once- and twice-daily dosing w ...... patients with type 2 diabetes.
@ast
Once- and twice-daily dosing w ...... patients with type 2 diabetes.
@en
P2093
P356
P1433
P1476
Once- and twice-daily dosing w ...... patients with type 2 diabetes.
@en
P2093
E B Rappaport
G Grunberger
L S Phillips
R Patwardhan
Rosiglitazone Clinical Trials Study Group
P304
P356
10.2337/DIACARE.24.2.308
P407
P577
2001-02-01T00:00:00Z